Published in final edited form as:

Ann Neurol. 2015 April ; 77(4): 668–674. doi:10.1002/ana.24365.

Clinical phenotypes as predictors of the outcome of skipping around *DMD* exon 45

Andrew R. Findlay^{1,*}, Nicolas Wein¹, Yuuki Kaminoh¹, Laura E. Taylor¹, Diane M. Dunn⁴, Jerry R. Mendell^{1,2,3}, Wendy M. King³, Alan Pestronk⁵, Julaine M. Florence⁵, Katherine D. Mathews⁶, Richard S. Finkel^{7,†}, Kathryn J. Swoboda⁸, Michael T. Howard⁴, John W. Day^{9,‡}, Craig McDonald¹⁰, Aurélie Nicolas^{11,12}, Elisabeth Le Rumeur^{11,12}, Robert B. Weiss⁴, and Kevin M. Flanigan^{1,2,3} for the United Dystrophinopathy Project

¹The Center for Gene Therapy, Nationwide Children's Hospital, Columbus, Ohio

²Department of Pediatrics, The Ohio State University, Columbus, Ohio

³Department of Neurology, The Ohio State University, Columbus, Ohio

⁴Department of Human Genetics, The University of Utah School of Medicine, Salt Lake City, Utah

⁵Department of Neurology, Washington University at St. Louis, St. Louis, Missouri

⁶Department of Pediatrics and Neurology, University of Iowa Carver College of Medicine, Iowa City, Iowa

⁷Division of Neurology, Nemours Children's Hospital, Orlando, Florida

⁸Department of Neurology, University of Utah School of Medicine, Salt Lake City, Utah

⁹Department of Neurology, University of Minnesota, Minneapolis, Minnesota

¹⁰Department of Physical Medicine and Rehabilitation, University of California Davis, Sacramento, California

¹¹Université de Rennes 1, Avenue du Professeur Léon Bernard, 35043 Rennes, France

¹²CNRS UMR 6290, Institut de Génétique et Développement de Rennes, 35043 Rennes, France

Abstract

Objective—Exon-skipping therapies aim to convert Duchenne muscular dystrophy (DMD) into less severe Becker muscular dystrophy (BMD) by altering pre-mRNA splicing to restore an open reading frame, allowing translation of an internally deleted and partially functional dystrophin protein. The most common single exon deletion – exon 45 (–45) – may theoretically be treated by skipping of either flanking exon (44 or 46). We sought to predict the impact of these by assessing the clinical severity in dystrophinopathy patients.

Address correspondence to: Kevin M. Flanigan, MD, The Center for Gene Therapy, The Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, Ohio 43205, Ph: 614-460-0775, kevin.flanigan@nationwidechildrens.org.

*Current addresses: Department of Neurology, Washington University at St. Louis, St. Louis, Missouri

†Division of Neurology, Nemours Children's Hospital, Orlando, Florida

‡Departments of Neurology, Pediatrics, and Pathology, Stanford University School of Medicine, Stanford, California

Methods—Phenotypic data including clinical diagnosis, age at wheelchair use, age at loss of ambulation, and presence of cardiomyopathy was analyzed from 41 dystrophinopathy patients containing equivalent in-frame deletions.

Results—As expected, deletions of either exons 45-47 (45–47) or exons 45-48 (45–48) result in BMD in 97% (36/37) of subjects. Unexpectedly, deletion of exons 45-46 (45–46) is associated with the more severe DMD phenotype in 4/4 subjects despite an in-frame transcript. Notably, no patients with a deletion of exons 44-45 (44–45) were found within the UDP database, and this mutation has only been reported twice before, which suggests an ascertainment bias attributable to a very mild phenotype.

Interpretation—The observation that 45-46 patients have typical DMD suggests that the conformation of the resultant protein may result in protein instability or altered binding of critical partners. We conclude that in DMD patients with 45, skipping of either exon 44 or multi-exon skipping of exons 46 and 47 (or exons 46-48) are better potential therapies than skipping of exon 46 alone.

Keywords

Dystrophinopathy; exon skipping; in-frame mutation; ambulation

BACKGROUND

The progressive muscle diseases Duchenne (DMD) and Becker muscular dystrophy (BMD) both result from mutations in the *DMD* gene, which encodes the dystrophin protein. DMD is associated with mutations that interrupt the messenger RNA (mRNA) open reading frame, resulting in severe muscle weakness and, typically, death before the age of 30^{1, 2}. In contrast, BMD is typically associated with mutations that maintain the open reading frame, producing an internally altered but partially functional dystrophin protein, with an intact C terminal domain^{1, 3}. BMD patients have variable phenotypes, but are less severely affected, and have a much longer to normal life expectancy³. Antisense oligonucleotides (AONs), a promising experimental line of molecular therapy for DMD, aim to restore gene expression by altering splicing at the pre mRNA level. These AONs hybridize to specific target sequence and can lead to skipping of a targeted exon⁴, resulting in restoration of an open reading frame, production of an internally truncated dystrophin protein, and conversion of the DMD phenotype to BMD. AONs are currently in phase 2 clinical trials for treatment of deletion mutations by exon 51 skipping^{5, 6}.

Exon 45 is the most common single exon deletion. In nearly all cases, this mutation is associated with DMD rather than BMD, including in 100% of 13 45 patients in a recent United states series⁷; in 97% (60 of 62) of patients in the UMD-DMD database^{7, 8}; in 15 of 18 (83%) of the patients with defined phenotypes in the United Dystrophinopathy Project database⁹; and in 93% (263 of 284) of the patients with defined phenotypes in the Leiden database (<http://www.dmd.nl/>)¹⁰. Exon-skipping therapies intended to treat 45 patients are currently in development, and multiple strategies to restore the reading frame exist for these patients. In addition to skipping of either exon 44 or 46, multi-exon skipping of 46-47 or 46-48 would restore the reading frame, and recent studies using adeno-associated virus

(AAV) mediated gene delivery of U7 small nuclear ribonucleoproteins (snRNPs) have shown efficient in-vivo skipping of up to three consecutive exons¹¹. However, not all internally truncated proteins are expected to be equivalent in function, or equivalent in expression.

To assess the likely outcomes of exon skipping therapies for DMD patients with 45, we utilized the United Dystrophinopathy Project (UDP) database of genotype, phenotype, and natural history data, to analyze patients with equivalent in frame deletions of exons 44-45, 45-46, 45-47, or 45-48.

METHODS

Subject Ascertainment

All patients were enrolled in the United Dystrophinopathy Project (UDP), which began enrollment in 2004; the last of these patients enrolled in June 2012. The UDP is a database of genotype, phenotype, and natural history data assembled by a multicenter consortium of neuromuscular physicians. Patient entry into the UDP is described elsewhere⁹. Briefly, patient entry required a dystrophinopathy diagnosis based on clinical features of DMD or BMD along with confirmation by an X-linked family history, muscle biopsy, or *DMD* gene testing. All enrolled patients underwent *DMD* gene testing. Based upon age at loss of ambulation (LOA), patients were classified as DMD (LOA by age 12), intermediate muscular dystrophy (LOA between ages 12 and 15), or BMD (LOA after age 15). Patients who had not yet lost ambulation were classified based upon an expert clinician diagnosis (as described elsewhere)⁹, taking into account age at presentation, clinical history in affected family members, steroid treatment, and muscle biopsy results (when available). Although clinical categorization by these criteria may not be perfect, unpublished data from the UDP suggest that revision of the original diagnosis occurs in less than 2% of cases. Dystrophinopathy phenotype analysis included ambulatory status, wheelchair use, cardiomyopathy, use of ventilatory support, steroid use and scoliosis surgery.

Cell Culture, Transdifferentiation, and RNA Analysis

Primary fibroblast cell lines from one patient were established following skin biopsy and immortalized via infection with two lentiviruses either containing human telomerase (hTER) or doxycycline-inducible MyoD construct. Following treatment of cultures with doxycycline (4µg/ml) for three days, transdifferentiation is evident by morphology and expression of myogenic genes, including dystrophin. For analysis of splicing, total RNA was isolated by standard techniques (Trizol, Life Technologies) for reverse transcription (Maxima reverse transcriptase, Thermo Scientific) followed by PCR (PCR Master Mix, Promega) using primer pairs located in exon 42 and exon 49.

RESULTS

We identified 41 male patients enrolled in the UDP database carrying in-frame deletions equivalent to a DMD patient with 45 receiving exon skipping therapy (Table 1). These genotypes included 45-46 (n=4), 45-47 (n=17), and 45-48 (n=20). No patients were identified with 44-45. All 4 patients with 45-46 carried a diagnosis of DMD. In contrast,

all 17 patients with 45-47, 19/20 patients with 45-48 carried a diagnosis of BMD, and the remaining patient was diagnosed with IMD.

The ages at examination and at loss of ambulation are represented in Figure 1. The mean age at last examination of the four patients with 45-46 was 10.5 years. Two had lost ambulation at ages 10 and 11.5 (mean = 10.75 years); the remaining two were ambulant at the last examination at ages 9.8 and 10.1. Among the 45-47 patients, the mean age at last examination was 30.8 years (range, 7 to 53.1), and only one patient (6%) had entirely lost ambulation, at the age of 38.5 years. Among the 45-48 patients, the mean age at last examination was 31.3 years (range, 4.5 to 65.3). Only 4 of 20 (20%) were non-ambulant, having lost ambulation at the mean age of 49.3 years (range, 34–62).

Patients were evaluated for cardiomyopathy, defined as an ejection fraction of less than 55% or a shortening fraction less than 28%. Echocardiograms were available for two of the four 45-46 patients, neither of whom had evidence of cardiomyopathy when echocardiograms were performed at 8.3 or 8.4 years of age. Nine 45-47 patients had echocardiograms, two of whom (22%) had been diagnosed with cardiomyopathy at an average age of 26.9 years; the average age of 45-47 patients without cardiomyopathy was 22.9 years. Nine of the 45-48 patients had echocardiograms, four of whom (44%) were diagnosed with cardiomyopathy at an average age of 48.0 years, whereas the average age of 45-48 patients without cardiomyopathy was 29.5 years.

We sought to evaluate exon splicing in 45-46 DMD patients. None had archived muscle tissue specimens available, and only one had an archived fibroblast specimen. Following MyoD transformation of the primary fibroblast cell line, RT-PCR analysis of *DMD* mRNA using primers located in exon 42 (forward) and exon 49 (reverse) revealed no evidence of alternatively spliced transcripts, and only the expected in-frame transcript was detected.

DISCUSSION

To deduce the potential therapeutic efficacy of an exon skipping therapy for 45 DMD patients, we searched the UDP database for patients with the equivalent in-frame mutations. One such group of patients carried 45-46 and all were diagnosed with DMD, representing an exception to the reading frame rule. Such exceptions are relatively common, as only 63% of patients with in-frame, non-truncating mutations carry a diagnosis of BMD or intermediate muscular dystrophy (IMD)⁹.

These exceptions have been attributed to mutations located in indispensable areas of the protein, such as the cysteine-rich or actin binding domains, or due to alternative splicing events that create out-of-frame transcripts^{10, 12}. At least seven alternatively spliced transcripts involving exons 44–58 have been identified in wild type skeletal muscle, and 5 novel alternative splicing events were activated in skeletal muscle of BMD patients carrying deletions within the rod domain, a mutational hot-spot of the *DMD* gene^{12, 13}. UDP patients with 45-46 might deviate from the reading frame rule because of alternative splicing of additional exons, resulting in an out-of-frame transcript. For example, an out-of-frame transcript would be generated in 45-46 patients by splicing of exon 44, which is easily

skipped and is often spontaneously spliced out when surrounding exons are deleted in experimental systems^{14, 15}. Unfortunately, muscle tissue from any of the four UDP patients with 45-46 was not available for mRNA or protein studies, limiting our analysis to *DMD* mRNA obtained from MyoD-transformed fibroblasts from one of these subjects; although a single sample presents only limited evidence, this model did not show such alternate splicing.

Another possible explanation for the severe phenotype seen in 45-46 patients could be due to involvement of the binding site for neuronal nitric oxide synthase mu (nNOS μ) which binds spectrin-like repeats 16 and 17 and is encoded by exons 42-45 in the *DMD* gene. In BMD patients with in-frame deletions of exons 45-55, the severity of muscle weakness and histopathology was associated with cytosolic mislocalization of nNOS μ ¹⁶. However, muscle from 12 patients with BMD due to 45-47, 45-48, or 45-49 showed levels of sarcolemmal nNOS staining to actually be lower than levels in muscle from 9 DMD patients with mutations treatable by skipping of exons 44 or 45¹⁷. These results argue strongly against differential nNOS binding as being the likely explanation for the comparable severity of the 45-46 phenotype.

We explored whether an alternative explanation might lie in the phasing of the spectrin repeats resulting from the in-frame transcript. We note that although most of the patients in our cohort had not lost ambulation, the mean age at loss of ambulation in the 45-48 cohort was comparable to that found in the same genotypic cohort of Nicolas et al (47 years)¹⁸, in which differences in age at LOA and onset of cardiomyopathy among subjects with 45-47, 45-48, and 45-49 mutations were shown to be associated with stability of the resultant peptide. In particular, those mutations resulting in the formation of fractional as opposed to hybrid spectrin repeats were associated with a more severe phenotype. However, the modeling of the proteins resulting from 44-45 and 45-46 predicts that both should result in comparable stable hybrid repeats (Fig. 2).

These observations have therapeutic implications. For patients with isolated 45, skipping of either exon 44 or exon 46 would restore an open reading frame, and AONs to skip either exon are in development. One study tested AON-induced skipping of exon 46 in primary myoblasts from patients with a deletion of exon 45, justifying their strategy by suggesting that “exon (45+46) deletions cause only a mild form of BMD,” although no source was provided for this information¹⁹. In fact, 11 of 22 (50%) patients reported with deletions of exons 45-46 have been described as DMD^{9, 10, 20-27}, and consistent with this, protein studies have been reported in a single 45-46 patient which revealed less than 5% of normal dystrophin staining on muscle biopsy²². Even allowing for possible differences among authors in applying dystrophinopathy classification, the frequency of the DMD phenotype in association with 45-46 suggests that skipping of exon 46 is a poor treatment option for patients with exon 45 deletions and – given the presence of some clinical heterogeneity in 45 patients – has the potential to actually worsen a given patient’s outcome.

An alternative strategy for restoring the reading frame in patients with 45 is to skip exon 44. The equivalent in-frame mutation, 44-45, was not present in the UDP database and has been reported within the literature only twice^{10, 21}. One of the patients with 44-45 was

labeled as DMD in a review of Leiden database patients carrying mutations that do not follow the reading frame rule¹⁰, but analysis of the original article in which the patient was first reported indicated that no definitive diagnosis was given²⁸. The second patient with 44-45 was given a diagnosis of DMD, but no diagnostic criteria or clinical data were provided²¹. Furthermore, the patient was genotyped using multiplex PCR which may not characterize the extent of deletions as accurately as multiplex ligation dependent probe amplification (MLPA), as it does not interrogate all exons. Since deletions beginning in intron 43 as well as deletions ending in intron 45 are both common breakpoints found in *DMD* deletions^{8–10}, a cold spot for deletion formation is an unlikely explanation for the paucity of 44-45 patients. Two cases of 45 patients with such alternative splicing of exon 44 in muscle have been reported. The first patient carried a diagnosis of DMD and was found to have 44-45 transcript expressed at less than 1% of normal levels, hypothesized to be enough to create revertant fibers but insufficient to alter the patient's phenotype²⁹. A second 45 patient remained ambulant until the age of 18 and was found to express a 44-45 alternatively spliced transcript at 6% of the total DMD mRNA, suggesting this level of in-frame transcript was sufficient to change the patient's phenotype to a milder form³⁰. Interestingly, the 44-45 dystrophin protein is very similar to wild type dystrophin with regards to folding thermodynamics and resistance to proteolysis³¹. We interpret the absence of 44-45 patients in our UDP cohort, which we expanded to more than 1100 subjects⁹ – and the near complete lack of 44-45 patients within all dystrophinopathy databases – to suggest that individuals with this mutation may be asymptomatic and do not seek medical attention.

Other treatment strategies include multi-exon skipping of exons 46-47, or 46-48. Although multi-exon skipping with AONs has been challenging¹⁵, efficient skipping of these exact exons has been achieved in mice using AAV-delivered U7 snRNPs¹¹. Among published reports, only 3.8% (13 of 342) 45-47 patients and 5.18% (13 of 251) 45-48 patients were diagnosed as DMD^{9, 10, 20–27}. Consistent with these reports, all 17 45-47 and 19 of the 20 45-48 patients within the UDP database had been diagnosed with BMD, and no significant differences in age at loss of ambulation or detection of cardiomyopathy were found for these patients.

The observations in this large cohort should be of interest in the design of future exon skipping approaches. They allow us to predict that in patients with isolated deletions of exon 45, skipping of exon 44 will result in a significantly better outcome than skipping of exon 46. Similarly, our data suggest that multi-exon skipping of either exons 46-47 or 46-48 is likely to result in a better treatment response than skipping of exon 46 alone.

Acknowledgments

This work was supported by the National Institute of Neurologic Diseases and Stroke (R01 NS043264 (K.M.F., M.T.H., R.B.W.))

References

1. Emery AE. The muscular dystrophies. *Lancet*. 2002 Feb 23; 359(9307):687–95. [PubMed: 11879882]

2. Passamano L, Taglia A, Palladino A, et al. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. *Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology/edited by the Gaetano Conte Academy for the study of striated muscle diseases*. 2012 Oct; 31(2):121–5.
3. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. *Genomics*. 1988 Jan; 2(1):90–5. [PubMed: 3384440]
4. van Deutekom JC, van Ommen GJ. Advances in Duchenne muscular dystrophy gene therapy. *Nat Rev Genet*. 2003 Oct; 4(10):774–83. [PubMed: 14526374]
5. Cirak S, Arechavala-Gomez V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. *Lancet*. 2011 Aug 13; 378(9791):595–605. [PubMed: 21784508]
6. Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. *N Engl J Med*. 2011 Apr 21; 364(16):1513–22. [PubMed: 21428760]
7. Cunliffe C, Andrews J, Meaney FJ, et al. Mutation analysis in a population-based cohort of boys with Duchenne or Becker muscular dystrophy. *J Child Neurol*. 2009 Apr; 24(4):425–30. [PubMed: 19074751]
8. Tuffery-Giraud S, Beroud C, Leturcq F, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. *Hum Mutat*. 2009 Jun; 30(6):934–45. [PubMed: 19367636]
9. Flanigan KM, Dunn DM, von Niederhausern A, et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. *Hum Mutat*. 2009 Dec; 30(12):1657–66. [PubMed: 19937601]
10. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. *Muscle Nerve*. 2006 Aug; 34(2):135–44. [PubMed: 16770791]
11. Goyenvall A, Wright J, Babbs A, Wilkins V, Garcia L, Davies KE. Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy. *Molecular therapy: the journal of the American Society of Gene Therapy*. 2012 Jun; 20(6):1212–21. [PubMed: 22354379]
12. Sironi M, Cagliani R, Pozzoli U, et al. The dystrophin gene is alternatively spliced throughout its coding sequence. *FEBS Lett*. 2002 Apr 24; 517(1–3):163–6. [PubMed: 12062429]
13. Sironi M, Cagliani R, Comi GP, et al. Trans-acting factors may cause dystrophin splicing misregulation in BMD skeletal muscles. *FEBS Lett*. 2003 Feb 27; 537(1–3):30–4. [PubMed: 12606026]
14. Wilton S, Fall A, Harding P, McClorey G, Coleman C, Fletcher S. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. *Molecular therapy: the journal of the American Society of Gene Therapy*. 2007; 15(7):1288–96. [PubMed: 17285139]
15. van Vliet L, de Winter CL, van Deutekom JC, van Ommen GJ, Aartsma-Rus A. Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. *BMC medical genetics*. 2008; 9:105. [PubMed: 19046429]
16. Gentil C, Leturcq F, Ben Yaou R, et al. Variable phenotype of del45-55 Becker patients correlated with nNOSmu mislocalization and RYR1 hypernitrosylation. *Human molecular genetics*. 2012 Aug 1; 21(15):3449–60. [PubMed: 22589245]
17. Anthony K, Arechavala-Gomez V, Ricotti V, et al. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping. *JAMA neurology*. 2014 Jan; 71(1):32–40. [PubMed: 24217213]
18. Nicolas A, Raguenes-Nicol C, Ben Yaou R, et al. Becker muscular dystrophy severity is linked to the structure of dystrophin. *Human molecular genetics*. 2014 Oct 27.

19. van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. *Human molecular genetics*. 2001 Jul 15; 10(15):1547–54. [PubMed: 11468272]
20. Lo IF, Lai KK, Tong TM, Lam ST. A different spectrum of DMD gene mutations in local Chinese patients with Duchenne/Becker muscular dystrophy. *Chin Med J (Engl)*. 2006 Jul 5; 119(13): 1079–87. [PubMed: 16834926]
21. Pandey GS, Kesari A, Mukherjee M, Mittal RD, Mittal B. Re-evaluation of reading frame-shift hypothesis in Duchenne and Becker muscular dystrophy. *Neurology India*. 2003 Sep; 51(3):367–9. [PubMed: 14652441]
22. Beggs AH, Hoffman EP, Snyder JR, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. *Am J Hum Genet*. 1991 Jul; 49(1):54–67. [PubMed: 2063877]
23. Niemann-Seyde S, Slomski R, Rininsland F, Ellermeyer U, Kwiatkowska J, Reiss J. Molecular genetic analysis of 67 patients with Duchenne/Becker muscular dystrophy. *Hum Genet*. 1992 Sep-Oct; 90(1–2):65–70. [PubMed: 1427789]
24. Carsana A, Frisso G, Tremolaterza MR, et al. Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity. *Annals of human genetics*. 2005 May; 69(Pt 3):253–9. [PubMed: 15845029]
25. Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. *Am J Hum Genet*. 1989 Oct; 45(4):498–506. [PubMed: 2491009]
26. Takeshima Y, Yagi M, Okizuka Y, et al. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. *Journal of human genetics*. 2010 Jun; 55(6):379–88. [PubMed: 20485447]
27. Todorova A, Todorov T, Georgieva B, et al. MLPA analysis/complete sequencing of the DMD gene in a group of Bulgarian Duchenne/Becker muscular dystrophy patients. *Neuromuscul Disord*. 2008 Aug; 18(8):667–70. [PubMed: 18653336]
28. Herczegfalvi A, Toth G, Gyurus P, et al. Deletion patterns of dystrophin gene in Hungarian patients with Duchenne/Becker muscular dystrophies. *Neuromuscul Disord*. 1999 Dec; 9(8):552–4. [PubMed: 10619712]
29. Prior TW, Bartolo C, Papp AC, et al. Dystrophin expression in a Duchenne muscular dystrophy patient with a frame shift deletion. *Neurology*. 1997 Feb; 48(2):486–8. [PubMed: 9040743]
30. Dwianingsih EK, Malueka RG, Nishida A, et al. A novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy. *J Hum Genet*. 2014 Aug; 59(8):423–9. [PubMed: 24871807]
31. Ruszczak C, Mirza A, Menhart N. Differential stabilities of alternative exon-skipped rod motifs of dystrophin. *Biochimica et biophysica acta*. 2009; 1794(6):921–8. [PubMed: 19286484]

United Dystrophinopathy Project: Other Investigators and Members

The University of Utah, Salt Lake City, Utah: Eduard Gappmaier, PhD; Payam Soltanzadeh, MD; Jacinda B. Sampson, MD, PhD; Mark B. Bromberg, MD, PhD; Russell Butterfield, MD, PhD; Lynne Kerr, MD, PhD; Kim Hart, MS; Cybil Moural, MS; Kate Hak, BS; Lahdan Heidarian, BS.

Nationwide Medical Center, Columbus, Ohio: Linda Lowes, DPT; Lindsay Alfano, PhD; Laurence Viollet, PhD; Chelsea Rankin, BS; Susan Gailey, MS.

Washington University, St. Louis, Missouri: Anne M. Connolly, MD; Glenn Lopate, MD; Paul Golumbek MD, PhD; Jeanine Schierbecker MHS, PT; Betsy Malkus MHS, PT; Renee Renna, RN; and Catherine Siener MHS, PT.

University of Iowa, Iowa City, Iowa: Carrie Stephan, RN; Karla Laubenthal, PT, MS, PCS; Kris Baldwin, LPT.

Children's Hospital/University of Pennsylvania, Philadelphia, Pennsylvania: Carsten G. Bonnemann, MD, PhD; Livija Medne, MS; Allan M. Glanzman, PT, DPT, PCS, ATP; Jean Flickinger, RPT.

Cincinnati Children's Hospital, Cincinnati, Ohio: Brenda Wong, MD; Paula Morehart, RN; Amy Meyer, PT.

University of Minnesota, Minneapolis, Minnesota: Cameron E. Naughton; Marcia Margolis, PT, ATP.

University of California Davis, Sacramento, California: R. Ted Abresch, MS, Michelle Cregan, CRA, Jay J. Han, MD, Eric Henricson, MPH, Linda Johnson, MPT

Figure 1. DMD genotypes vs. age at last evaluation

The clinical diagnosis of patients is noted below each genotype class. Non-ambulant patients are marked by filled squares.

Figure 2. Molecular modeling of dystrophin proteins predicted to result from deletions of (A) exons 44-45 and (B) exons 45-46

Each is predicted to result in a hybrid repeat that contains three helices in a coiled-coil pattern, as opposed to a fractional repeat, which would be predicted to be less stable. (A)

44-45 is composed of R15 (pink), part of R16 (blue) and part of R17 (purple), R18 (yellow). (B) 45-46 is composed of R16 (blue), part of R17 (purple) and part of R18 (yellow), R19 (grey).

Table 1
Summary of natural history data for patients included in the study

Age at which full or part-time wheelchair use occurred is noted in parentheses. **Dp140:** + marks patients in which a deletion of the Dp140 isoform promoter was detected; for all others, this promoter (found in intron 44) was present. **Clinical diagnosis** is the “expert clinician” diagnosis as discussed in the text. **Age** is the age at last evaluation/data collection. **Ambulation:** use of wheelchair (WC) and age at which used in years. **mMRC:** The mean Medical Research Council (mMRC) consists of the modified MRC score for each muscle examined, converted to a numerical (0–10 point) scale. The standard UDP evaluation grades 34 muscles. These values are summed and divided by the number of muscles actually examined. **LVEF:** Left ventricular ejection fraction (LVEF%) is shown for those patients for whom the data was provided, and the age at which it was obtained is shown in years. For patients with multiple echocardiograms, the LVEF% value and the date provided are for either the *first abnormal*, or if no abnormal results were seen, the *most recent normal* recorded echocardiogram.

Patient	Genotype	Dp140	Clinical Diagnosis	Age (y)	Ambulation Status (age at WC use in y)	mMRC	LVEF (%)	Age at LVEF (y)
1			DMD	9.8	WC part-time (8)			
2	45-46		DMD	10.1	WC part-time (7)	8.2	60	8.4
3			DMD	10.4	WC full-time (10)	5.8	61	8.3
4			DMD	11.6	WC full-time (11.5)	4.9		
5			BMD	7.0	Ambulant	6.6		
6			BMD	12.6	Ambulant	7.0	67	12.2
7			BMD	13.5	Ambulant	7.0	65	13.1
8			BMD	16.2	Ambulant	7.6	69	16.2
9			BMD	18.8	Ambulant	6.3	57	18.8
10			BMD	20.0	Ambulant	7.2	70	20.0
11			BMD	28.4	Ambulant	8.0	20	24.6
12			BMD	29.6	Ambulant	7.0	30	29.2
13	45-47		BMD	32.8	Ambulant	8.4		
14			BMD	33.2	ambulant			
15			BMD	35.7	Ambulant	7.4	62	38.5
16		+	BMD	38.6	WC full-time (38)	6.3		
17			BMD	41.8	Ambulant	6.9	57	41.8
18			BMD	44.9	Ambulant	8.1		
19			BMD	46.6	Ambulant	6.7		
20		+	BMD	50.4	Ambulant	7.5		

Patient	Genotype	Dp140	Clinical Diagnosis	Age (y)	Ambulation Status (age at WC use in y)	mMRC	LVEF (%)	Age at LVEF (y)
21			BMD	53.1	WC part-time (48)	7.8		
22			BMD	4.5	Ambulant			
23			IMD	5.3	Ambulant	7.0		
24			BMD	5.9	Ambulant	7.6	63	6.6
25			BMD	6.1	Ambulant	6.6		
26			BMD	9.0	Ambulant	7.6		
27			BMD	10.2	Ambulant	6.3	70	10.2
28			BMD	15.9	WC part-time (8)	8.4		
29		+	BMD	16.3	Ambulant	9.3		
30			BMD	20.8	Ambulant	9.4		
31	45-48		BMD	33.8	Ambulant	7.8	59	34.8
32			BMD	36.1	Ambulant			
33			BMD	37.6	Ambulant	7.8	59	36.6
34			BMD	41.8	Ambulant	6.8		
35			BMD	48.6	WC full-time (34)	5.7	48	39.2
36			BMD	50.5	Ambulant			
37			BMD	52.0	WC full-time (48)	4.5	50	47.3
38			BMD	52.5	Ambulant	6.0	22	52.5
39			BMD	52.9	Ambulant	6.1	50	52.9
40			BMD	60.1	WC full-time (53)	5.5	71	59.3
41			BMD	65.3	WC full-time (62)	5.1		60.0